Method Developed for Enriching Trophoblast Population in Samples
|
By LabMedica International staff writers Posted on 02 Sep 2019 |

Image: The transverse section of a chorionic villus (Photo courtesy of Wikimedia Commons).
A recent paper described a technique to increase the proportion of placental trophoblast cells in cervical samples by 700%, which enables individual trophoblasts to be picked out for genetic testing.
Currently, diagnosis of genetic disorders in developing fetuses requires capture of trophoblasts through amniocentesis or chorionic villus sampling, both invasive procedures. Extravillous trophoblasts (EVTs) have the potential to provide the entire fetal genome for prenatal testing. Previous studies have demonstrated the presence of EVTs in the cervical canal and the ability to retrieve a small quantity of these cells by cervical sampling. However, these small quantities of trophoblasts are greatly outnumbered by the population of cervical cells in the sample, making isolation of the trophoblasts difficult.
Investigators at Brown University (Providence, RI, USA) took advantage of differences in morphology between trophoblasts and other cervical cells (trophoblasts are smaller, differ in shape, and have relatively large nuclei) to develop a method to enrich the trophoblast population in a cervical sample through differential settling of the cells in polystyrene wells.
Initially the investigators added small quantities of JEG-3 trophoblast cell line cells into clinical samples from standard Pap tests taken at five to 20 weeks of gestation to determine the optimal workflow. They observed that a four-minute incubation period in the capture wells led to a maximum in JEG-3 cell settling onto the plastic surface with the removal of more than 90% of the cervical cell population, leading to a 700% enrichment in JEG-3 cells.
The investigators then went on to conduct a proof-of-concept study on an imaging and picking platform to demonstrate the ability to pick single trophoblast cells for whole genome amplification. Results showed that the new technique was quick, inexpensive, minimized cell loss, and yielded retrieval of individual trophoblast cells.
"There is a large need for biomedical engineering techniques toward advancing prenatal and women's health," said first author Christina Bailey-Hytholt, a doctoral research student in biomedical engineering at Brown University. "Our work is a step toward more non-invasive prenatal testing options."
The trophoblast enrichment technique was described in the August 20, 2019, online edition of the journal Scientific Reports.
Related Links:
Brown University
Currently, diagnosis of genetic disorders in developing fetuses requires capture of trophoblasts through amniocentesis or chorionic villus sampling, both invasive procedures. Extravillous trophoblasts (EVTs) have the potential to provide the entire fetal genome for prenatal testing. Previous studies have demonstrated the presence of EVTs in the cervical canal and the ability to retrieve a small quantity of these cells by cervical sampling. However, these small quantities of trophoblasts are greatly outnumbered by the population of cervical cells in the sample, making isolation of the trophoblasts difficult.
Investigators at Brown University (Providence, RI, USA) took advantage of differences in morphology between trophoblasts and other cervical cells (trophoblasts are smaller, differ in shape, and have relatively large nuclei) to develop a method to enrich the trophoblast population in a cervical sample through differential settling of the cells in polystyrene wells.
Initially the investigators added small quantities of JEG-3 trophoblast cell line cells into clinical samples from standard Pap tests taken at five to 20 weeks of gestation to determine the optimal workflow. They observed that a four-minute incubation period in the capture wells led to a maximum in JEG-3 cell settling onto the plastic surface with the removal of more than 90% of the cervical cell population, leading to a 700% enrichment in JEG-3 cells.
The investigators then went on to conduct a proof-of-concept study on an imaging and picking platform to demonstrate the ability to pick single trophoblast cells for whole genome amplification. Results showed that the new technique was quick, inexpensive, minimized cell loss, and yielded retrieval of individual trophoblast cells.
"There is a large need for biomedical engineering techniques toward advancing prenatal and women's health," said first author Christina Bailey-Hytholt, a doctoral research student in biomedical engineering at Brown University. "Our work is a step toward more non-invasive prenatal testing options."
The trophoblast enrichment technique was described in the August 20, 2019, online edition of the journal Scientific Reports.
Related Links:
Brown University
Latest BioResearch News
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
- Researchers Map Protein and Glycosylation Across 15 Human Body Fluids
- Telomere Length Abnormalities Linked to Lymphoma Development
- Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
- Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
- Study Links Abnormal Gene Splicing to Treatment Response in Metastatic Kidney Cancer
- Research Reveals How Some Aplastic Anemia Patients Recover Bone Marrow Function
- New Molecular Insights Support Diagnosis of Hodgkin Lymphoma
- Epigenetic Signals and Blood Markers Aid Chronic Fatigue Syndrome Diagnosis
- Microenvironment Biomarkers Could Enable Early Lung Cancer Detection
- Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
- Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
- Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
- Single-Cell Method Measures RNA and Proteins to Reveal Immune Responses
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
Channels
Clinical Chemistry
view channel
FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
Accurate evaluation of androgen status often requires concordant measurement of total testosterone, free testosterone, and sex hormone‑binding globulin. Reference methods such as equilibrium dialysis with... Read more
CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
Specialized care settings frequently evaluate patients aged 50 years and older who present with signs and symptoms of cognitive decline to determine whether amyloid pathology linked to Alzheimer’s disease... Read moreMolecular Diagnostics
view channel
Blood Test Refines Biopsy Decisions in Prostate Cancer
Prostate biopsy decisions remain challenging, with many men undergoing invasive procedures that ultimately yield negative results. In the U.S., more than a million prostate biopsies are performed each... Read more
Digital Aging Twin Quantifies Biological Aging Across Multiple Organ Systems
Chronological age often fails to capture the wide variability in physiological decline among adults, limiting risk stratification and long-term monitoring. Clinical laboratories also lack standardized... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read more
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read moreMicrobiology
view channel
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read more
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read more
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








